News & Updates

Negative upper endoscopy findings in patients with gastroesophageal reflux disease (GERD) indicate lower risk of developing upper gastrointestinal cancer, a new study has found.

Combining the neutrophil-to-lymphocyte (NLR) and platelet-to-lymphocyte (PLR) ratios with existing diagnostic methods helps improve early detection of second primary cancers (SPC) after initial gastric cancer (GC), a recent study has found.

Cancer patients receiving either low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) show comparable frequency of venous thromboembolism (VTE), reports a recent study.

The addition of a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor to fulvestrant provides a consistent benefit in overall survival (OS) in patients with hormone receptor (HR)–positive, HER2-negative, advanced or metastatic breast cancer in first-, second- and later-line settings and in most clinicopathological subgroups of interest, results of a US FDA pooled analysis of have shown.

Combining lenalidomide with R-CHOP* (R2CHOP) yields durable and high rates of treatment response in untreated patient with diffuse large B-cell lymphoma (DLBCL), a recent study has found.

Administering a device-based selective internal radiation therapy, in addition to systemic treatment in the second-line setting, extends time to progression in colorectal liver metastases patients, as shown in the phase III EPOCH trial.

Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has a dismal prognosis. However, immunotherapy survival benefits reported in KEYNOTE-522 and KEYNOTE-355 trials bring new hope for this indication. [Ann Oncol 2021;32:994-1004]

Recent research has found that mutations in the human EZH2 and CCND1 genes may be potential novel biomarkers for liver cancer. The tumour mutation burden (TMB) also appears to be an important prognostic factor and affects patient survival.